Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 Tablets in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

NCT07806175 is registered in ClinicalTrials.gov with Rongchang Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07806175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07806175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 Tablets in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Lead sponsor
Rongchang Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
August 15, 2029
Enrollment
486 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors